A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy

Journal of Clinical Psychiatry

Volumn 69, Issue 9, 2008, Pages 1383-1392

  Kornstein, Susan G ^a   Dunner, David L ^b   Meyers, Adam L ^c   Whitmyer, Virgil G ^c   Mallinckrodt, Craig H ^c   Wohlreich, Madelaine M ^c   Detke, Michael J ^c   Hollandbeck, Millie S ^c   Greist, John H ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Center for Anxiety and Depression   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Healthcare Technology Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PLACEBO;

ABNORMAL DREAMING; ADULT; AGED; ARTICLE; BACKACHE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE PAIN; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOMANIA; INSOMNIA; LIBIDO; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEMORY DISORDER; NAUSEA; ORTHOSTATIC HYPOTENSION; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SEDATION; SHOULDER PAIN; SIDE EFFECT; SINUS HEADACHE; SINUSITIS; SOMNOLENCE; SORE THROAT; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TOOTH ABSCESS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; UTERUS MYOMA; VOMITING; XEROSTOMIA;

EID: 52649178368     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0905     Document Type: Article

References (28)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200
2. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354(12):1243-1252
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 Mar;354(12):1231-1242
4. Kroenke K, Shen J, Oxman TE, et al. Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. Pain 2008 Jan;134(1-2):209-215
5. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry 2000 Jun;61(6):403-408
6. Rush AJ, Crismon ML, Toprac MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998;59(suppl 20):73-84
7. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-880
8. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-132
9. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 Apr;63(4):308-315
10. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
11. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002 Mar;63(3):225-231
12. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006;21:367-378
13. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 Dec;14(6):457-470
14. Wohlreich MM, Mallinckrodt CH, Prakash A, et al. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety 2007;24:41-52
15. Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007;23(6):1303-1318
16. Ruhe HG, Huyser J, Swinkels JA, et al. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 2006;189:309-316
17. Dunner DL, Kornstein SG, Whitmyer V, et al. Effects of initial dosing strategies of duloxetine on tolerability and efficacy in patients with major depressive disorder. Presented at the 45th annual meeting of the American College of Neuropsychiatry; December 3-7, 2006; Hollywood, Fla
18. Whitmyer VG, Dunner DL, Kornstein SG, et al. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 2007 Dec;68(12):1921-1930
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
20. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
22. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
23. Rush AJ, Carmody T, Reimitz P. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000;9(2):45-59
24. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54(5):573-583
25. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23(2):129-138
26. DeLoach LJ, Higgins MS, Caplan AB, et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86(1):102-106
27. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:217-222, 313-331
28. Michelson D, Schmidt M, Lee J, et al. Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment. J Sex Marital Ther 2001;27(3):289-302